Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors
David E Piccioni,
Achal Singh Achrol,
Lesli A Kiedrowski,
Kimberly C Banks,
Najee Boucher,
Garni Barkhoudarian,
Daniel F Kelly,
Tiffany Juarez,
Richard B Lanman,
Victoria M Raymond,
Minhdan Nguyen,
Judy D Truong,
Annie Heng,
Jaya Gill,
Marlon Saria,
Sandeep C Pingle,
Santosh Kesari
Affiliations
David E Piccioni
1Department of Neurosciences, University of California San Diego Moores Cancer Center, San Diego, CA, USA
Achal Singh Achrol
2Department of Translational Neurosciences and Neurotherapeutics, Pacific Neuroscience Institute, John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica, CA, USA
Lesli A Kiedrowski
3Department of Medical Affairs, Guardant Health, Redwood City, CA, USA
Kimberly C Banks
3Department of Medical Affairs, Guardant Health, Redwood City, CA, USA
Najee Boucher
2Department of Translational Neurosciences and Neurotherapeutics, Pacific Neuroscience Institute, John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica, CA, USA
Garni Barkhoudarian
2Department of Translational Neurosciences and Neurotherapeutics, Pacific Neuroscience Institute, John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica, CA, USA
Daniel F Kelly
2Department of Translational Neurosciences and Neurotherapeutics, Pacific Neuroscience Institute, John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica, CA, USA
Tiffany Juarez
2Department of Translational Neurosciences and Neurotherapeutics, Pacific Neuroscience Institute, John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica, CA, USA
Richard B Lanman
3Department of Medical Affairs, Guardant Health, Redwood City, CA, USA
Victoria M Raymond
3Department of Medical Affairs, Guardant Health, Redwood City, CA, USA
Minhdan Nguyen
2Department of Translational Neurosciences and Neurotherapeutics, Pacific Neuroscience Institute, John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica, CA, USA
Judy D Truong
2Department of Translational Neurosciences and Neurotherapeutics, Pacific Neuroscience Institute, John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica, CA, USA
Annie Heng
2Department of Translational Neurosciences and Neurotherapeutics, Pacific Neuroscience Institute, John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica, CA, USA
Jaya Gill
2Department of Translational Neurosciences and Neurotherapeutics, Pacific Neuroscience Institute, John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica, CA, USA
Marlon Saria
2Department of Translational Neurosciences and Neurotherapeutics, Pacific Neuroscience Institute, John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica, CA, USA
Sandeep C Pingle
1Department of Neurosciences, University of California San Diego Moores Cancer Center, San Diego, CA, USA
Santosh Kesari
2Department of Translational Neurosciences and Neurotherapeutics, Pacific Neuroscience Institute, John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica, CA, USA
Aim: Genomically matched trials in primary brain tumors (PBTs) require recent tumor sequencing. We evaluated whether circulating tumor DNA (ctDNA) could facilitate genomic interrogation in these patients. Methods: Data from 419 PBT patients tested clinically with a ctDNA NGS panel at a CLIA-certified laboratory were analyzed. Results: A total of 211 patients (50%) had ≥1 somatic alteration detected. Detection was highest in meningioma (59%) and gliobastoma (55%). Single nucleotide variants were detected in 61 genes, with amplifications detected in ERBB2, MET, EGFR and others. Conclusion: Contrary to previous studies with very low yields, we found half of PBT patients had detectable ctDNA with genomically targetable off-label or clinical trial options for almost 50%. For those PBT patients with detectable ctDNA, plasma cfDNA genomic analysis is a clinically viable option for identifying genomically driven therapy options.
